Intravitreal Triamcinolone Acetonide monotherapy as an alternative treatment modality for retinitis post-febrile illness
Accept poster if oral is not possible ?
Yes
Purpose
To describe clinical profile, imaging characteristics, visual outcomes, and resolution patterns of retinitis post-febrile illness (PFR) treated with Intravitreal triamcinolone acetonide (IVTA) alone and to assess its efficacy and safety.
Methods
Single center, retrospective, observational analysis of patients with PFR
Results
We report 37 eyes of 24 cases with mean-age 41.5 years (11 unilateral, 13 bilateral). 22 cases were males, while 2 were females. Retinitis lesions were either multifocal (n=25) or unifocal (n=12). All the retinitis lesions healed with variable retinal thinning. Mean time for resolution of PFR lesions was 13.25 weeks. Patterns of resolution noted were centripetal and/or breadcrumb like. Two eyes showed increased intraocular pressure post injection, which was managed with oral pressure lowering agents. We did not observe any treatment failures, cataract formation or signs of infection post IVTA injection. There was statistically significant visual improvement after injection at 3 month follow up
Conclusion
We observed overall favorable visual outcomes and anatomical outcomes after IVTA, with resolution of lesions in cases of retinitis post-febrile illness. Thus this study highlights the usage of IVTA as an effective and relatively safer alternative treatment option for PFR, thereby negating the need for systemic steroids and hence preventing its side effects.
Conflict of interest
No
1
Last name
JADHAV
Initials of first name(s)
V S
Department
Anant Bajaj Retina Institute and Uveitis Services
City
Visakhapatnam
Country
India
2
Last name
Kelgaonkar
Initials of first name(s)
A N
Department
Anant Bajaj Retina Institute and Uveitis Services
City
Bhubaneswar
Country
India
3
Last name
Basu
Initials of first name(s)
S
Department
Saroja A Rao Center for Uveitis
City
Hyderabad
Country
India
This website uses cookies to ensure you get the best experience on our website.
Learn more